<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03476629</url>
  </required_header>
  <id_info>
    <org_study_id>PAH Rehabilitation</org_study_id>
    <nct_id>NCT03476629</nct_id>
  </id_info>
  <brief_title>Effects of Different Types of Physical Training in Patients With Pulmonary Arterial Hypertension.</brief_title>
  <acronym>PAH</acronym>
  <official_title>Effects of Combined Training Versus Aerobic Training Versus Respiratory Muscle Training in Patients With Pulmonary Hypertension: A Randomized, Controlled Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nove de Julho</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Faculdade de Ciências Médicas da Santa Casa de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nove de Julho</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although there has been some progress in pharmacological management of PAH, limited
      functional capacity and low survival still persist, but there is evidence that exercise
      training can be accomplished without adverse effects or damage to cardiac function and
      pulmonary hemodynamics. Specifically, improvements in symptoms, exercise capacity, peripheral
      muscle function and quality of life. Training programs need to be better studied and well
      defined, and their physiological effects during physical training and functional capacity.

      The aim of this study is to compare the effects of different training exercises on physical
      performance indicators.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary arterial hypertension (PAH) is characterized by pathological changes in the
      pulmonary vasculature which cause an increase in pulmonary vascular resistance (PVR),
      restricting the flow of blood through the pulmonary circulation. It is a serious illness,
      progressive and usually fatal which causes significant functional limitation, mainly due to
      dyspnea. In order to maintain the flow of blood, pulmonary artery pressure (PAP) increases
      and the disease progresses leading to right ventricular dysfunction and right heart failure.

      Regardless of the cause of PAH, the pulmonary arteries and arterioles have reduced capacity,
      and increases in cardiac output during exercise is limited. As a result, the delivery of
      oxygen to peripheral muscles is impaired, contributing to the symptoms of fatigue and
      dyspnea. While the limitation of the cardiac output to meet peripheral oxygen demand during
      exercise largely reduces exercise capacity, musculoskeletal dysfunction may also be involved
      in the exercise limitation in patients with PAH. Changes such as, muscle atrophy, decreased
      oxidative enzymes and a greater number of type II muscle fibers lead to an early lactic
      acidosis and decreased functional capacity. A modest evidence exists that exercise training
      can be done without adverse effects or damage to cardiac and / or pulmonary hemodynamics
      however, the effectiveness PAH requires more research.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 10, 2016</start_date>
  <completion_date type="Anticipated">December 10, 2019</completion_date>
  <primary_completion_date type="Actual">July 10, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional exercise capacity</measure>
    <time_frame>Change from Baseline to 15 weeks</time_frame>
    <description>Oxygen consumption measurement during cardiopulmonary test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 Minute Walking Test</measure>
    <time_frame>Change from Baseline to 15 weeks</time_frame>
    <description>Distance in meters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incremental shuttle walking test</measure>
    <time_frame>Change from Baseline to 15 weeks</time_frame>
    <description>Distance in meters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Autonomic Nervous System</measure>
    <time_frame>Change from Baseline to 15 weeks</time_frame>
    <description>Assesment by Heat Rate Variability analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Muscle Strength</measure>
    <time_frame>Change from Baseline to 15 weeks</time_frame>
    <description>Assesment by Test of Incremental Respiratory Endurance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Musculoskeletal Function</measure>
    <time_frame>Change from Baseline to 15 weeks</time_frame>
    <description>Assesment by peripheral muscular strength testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of laboratory parameters, metabolic profile assessment and systemic inflammatory.</measure>
    <time_frame>Change from Baseline to 15 weeks</time_frame>
    <description>IL-1beta, IL-1ra, IL-6, IL-8, IL-10 and TNF-alfa (pg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exhaled Nitric Oxide</measure>
    <time_frame>Change from Baseline to 15 weeks</time_frame>
    <description>The fraction of eNO (exhaled nitric oxide) in air will be measured by chemiluminescence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function (physiological parameter)</measure>
    <time_frame>Change from Baseline to 15 weeks</time_frame>
    <description>Forced vital capacity and liters in 1 second, Total lung capacity, diffusion of carbon dioxide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Activity Questionnaire (IPAQ)</measure>
    <time_frame>Change from Baseline to 15 weeks</time_frame>
    <description>The level of physical activity will be assessed using the international questionnaire short-version physical activity (IPAQ). The continuous score allows assessing energy expenditure expressed in MET minutes/week. The IPAQ categorical classifies include: Insufficiently active (does not perform any physical activity); Sufficiently active (conducts vigorous activity at least three days a week &gt;600 MET - 1400 MET); Very active (performs more than three days per week of vigorous activity 1500 MET - 3000 MET)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>Change from Baseline to 15 weeks</time_frame>
    <description>Endothelial function will be assessed by flow-mediated dilation (FMD)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Respiratory Disease</condition>
  <condition>Hypertension, Pulmonary</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Combined Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined Training with 2 types of physical activity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Physical activity with aerobic exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Respiratory Muscle Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Respiratory muscle performance</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical activity</intervention_name>
    <description>Effects of different physical activity programs</description>
    <arm_group_label>Combined Training</arm_group_label>
    <arm_group_label>Standard Training</arm_group_label>
    <arm_group_label>Respiratory Muscle Training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having confirmed diagnosis of PAH, based on elevated pressure in the pulmonary artery
             measured by catheterization of the heart at rest, with WHO functional (World Health
             Organization's - Functional Assessment for Pulmonary Hypertension - modified after New
             York Heart Association Functional Classification (NYHA) functional classification)
             classes I, II, III or IV to capture PAH patients with pré-capillary involvement;

          -  Clinically stable with no previous hospitalizations in the last four weeks;

          -  Receiving PAH specific drug therapy for at least 3 months before the study began.

        Exclusion Criteria:

          -  Use of continuous oxygen therapy;

          -  Significant musculoskeletal disease or pain / claudication members;

          -  Neurologic or cognitive impairment, psychiatric disorders or psychological mood
             (making it difficult for patients to understand the required tests);

          -  History of moderate or severe chronic lung disease;

          -  PAH patients with post-capillary involvement.

          -  Cardiac disease associated with cardiac failure, angina and / or unstable heart
             rhythm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luciana Malosá Sampaio, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nove de Julho</affiliation>
  </overall_official>
  <reference>
    <citation>Desai SA, Channick RN. Exercise in patients with pulmonary arterial hypertension. J Cardiopulm Rehabil Prev. 2008 Jan-Feb;28(1):12-6. doi: 10.1097/01.HCR.0000311502.57022.73. Review. Erratum in: J Cardiopulm Rehabil Prev. 2008 Mar-Apr;28(2):table of contents.</citation>
    <PMID>18277824</PMID>
  </reference>
  <reference>
    <citation>Schannwell CM, Steiner S, Strauer BE. Diagnostics in pulmonary hypertension. J Physiol Pharmacol. 2007 Nov;58 Suppl 5(Pt 2):591-602. Review.</citation>
    <PMID>18204173</PMID>
  </reference>
  <reference>
    <citation>Gabbay E, Reed A, Williams TJ. Assessment and treatment of pulmonary arterial hypertension: an Australian perspective in 2006. Intern Med J. 2007 Jan;37(1):38-48. Review.</citation>
    <PMID>17199843</PMID>
  </reference>
  <reference>
    <citation>Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997 Jan 9;336(2):111-7. Review.</citation>
    <PMID>8988890</PMID>
  </reference>
  <reference>
    <citation>Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M; ESC Scientific Document Group . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29.</citation>
    <PMID>26320113</PMID>
  </reference>
  <reference>
    <citation>Arena R, Lavie CJ, Milani RV, Myers J, Guazzi M. Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: an evidence-based review. J Heart Lung Transplant. 2010 Feb;29(2):159-73. doi: 10.1016/j.healun.2009.09.003. Epub 2009 Dec 6.</citation>
    <PMID>19969471</PMID>
  </reference>
  <reference>
    <citation>Naeije R. Breathing more with weaker respiratory muscles in pulmonary arterial hypertension. Eur Respir J. 2005 Jan;25(1):6-8.</citation>
    <PMID>15640315</PMID>
  </reference>
  <reference>
    <citation>Bauer R, Dehnert C, Schoene P, Filusch A, Bärtsch P, Borst MM, Katus HA, Meyer FJ. Skeletal muscle dysfunction in patients with idiopathic pulmonary arterial hypertension. Respir Med. 2007 Nov;101(11):2366-9. Epub 2007 Aug 6.</citation>
    <PMID>17689235</PMID>
  </reference>
  <reference>
    <citation>Mainguy V, Maltais F, Saey D, Gagnon P, Martel S, Simon M, Provencher S. Effects of a rehabilitation program on skeletal muscle function in idiopathic pulmonary arterial hypertension. J Cardiopulm Rehabil Prev. 2010 Sep-Oct;30(5):319-23. doi: 10.1097/HCR.0b013e3181d6f962.</citation>
    <PMID>20410828</PMID>
  </reference>
  <reference>
    <citation>de Man FS, Handoko ML, Groepenhoff H, van 't Hul AJ, Abbink J, Koppers RJ, Grotjohan HP, Twisk JW, Bogaard HJ, Boonstra A, Postmus PE, Westerhof N, van der Laarse WJ, Vonk-Noordegraaf A. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2009 Sep;34(3):669-75. doi: 10.1183/09031936.00027909.</citation>
    <PMID>19720810</PMID>
  </reference>
  <reference>
    <citation>Meyer FJ, Lossnitzer D, Kristen AV, Schoene AM, Kübler W, Katus HA, Borst MM. Respiratory muscle dysfunction in idiopathic pulmonary arterial hypertension. Eur Respir J. 2005 Jan;25(1):125-30.</citation>
    <PMID>15640333</PMID>
  </reference>
  <reference>
    <citation>Kabitz HJ, Schwoerer A, Bremer HC, Sonntag F, Walterspacher S, Walker D, Schaefer V, Ehlken N, Staehler G, Halank M, Klose H, Ghofrani HA, Hoeper MM, Gruenig E, Windisch W. Impairment of respiratory muscle function in pulmonary hypertension. Clin Sci (Lond). 2008 Jan;114(2):165-71.</citation>
    <PMID>17764445</PMID>
  </reference>
  <reference>
    <citation>Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation. 2004 Sep 7;110(10):1308-12. Epub 2004 Aug 30.</citation>
    <PMID>15337703</PMID>
  </reference>
  <reference>
    <citation>Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, Meyer FJ, Karger G, Buss J, Juenger J, Holzapfel N, Opitz C, Winkler J, Herth FF, Wilkens H, Katus HA, Olschewski H, Grünig E. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006 Oct 3;114(14):1482-9. Epub 2006 Sep 18.</citation>
    <PMID>16982941</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2018</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nove de Julho</investigator_affiliation>
    <investigator_full_name>LUCIANA MARIA MALOSA SAMPAIO</investigator_full_name>
    <investigator_title>Professor of the Postgraduate Program in Rehabilitation Sciences</investigator_title>
  </responsible_party>
  <keyword>Cardiopulmonary Exercise Test</keyword>
  <keyword>Rehabilitation</keyword>
  <keyword>Distance Traveled</keyword>
  <keyword>Functional Capacity</keyword>
  <keyword>Autonomic Nervous System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

